Filtered By:
Specialty: Neurology
Source: Neurology
Education: Study
This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 1979 results found since Jan 2013.
Patient-Reported Outcome Measurement in Manual Ability for Multiple Sclerosis: Addressing the Targeting Issues of the ABILHAND (P3.364)
Conclusions:Our study suggests that complementing the ABILHAND with bolt-on items appears to provide additional clinically relevant and targeted measurement of manual ability and related impact in early stage patients. To confirm this, ABILHAND along with new bolt-on items should be tested in a larger clinically-defined sample to evaluate its measurement properties (including measurement coverage and precision) in RRMS.Study Supported by: This study was funded by Biogen.Disclosure: Dr. Chen has received personal compensation for activities with Biogen as an employee. Dr. Chen holds stock and/or stock options in Biogen. Dr....
Source: Neurology - April 17, 2017 Category: Neurology Authors: Chen, S.-Y., Pompilus, F., Strzok, S., Cleanthous, S., Cano, S., Marquis, P., Cohan, S., Goldman, M., Kresa-Reahl, K., Petrillo, J., Castrillo-Viguera, C., Cadavid, D., Mellion, M. Tags: Quality of Life, Symptoms and Symptomatic Therapy, Comorbidity, and Patient Reported Outcomes in Multiple Sclerosis Source Type: research
Virtual research visits in individuals with Parkinson disease enrolled in a clinical trial: REACT-PD Study Interim Analysis (P4.005)
Conclusions:To our knowledge, this is the first study directly comparing remote assessments to in-person assessments in a clinical trial. These results will inform the feasibility, reliability, and value of conducting clinical trials virtually and may serve as a model for increasing access, participation, and retention in clinical trials.Study Supported by: AMC Health, National Institute of Neurological Disorders and Stroke (P20 NS092529)Disclosure: Dr. Tarolli has nothing to disclose. Dr. Andrzejewski has nothing to disclose. Dr. Bull has nothing to disclose. Dr. Goldenthal has nothing to disclose. Dr. O'Brien has receive...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Tarolli, C., Andrzejewski, K., Bull, M., Goldenthal, S., OBrien, M., Simuni, T., Zimmerman, G., Biglan, K., Dorsey, E. R. Tags: Parkinson ' s Disease: Therapeutics and Telehealth II Source Type: research
Effect of early use of AbobotulinumtoxinA (Dysport(R)) after stroke on spasticity progression: first results of a pilot study (P4.032)
Conclusions:Median time between first injection (administered in patients 2–12 weeks post-stroke, MAS ≥2) and appearance of reinjection criteria (signs of symptomatic spasticity) was statistically significantly longer with aboBoNT-A compared with placebo. Safety profile was consistent with the known profile of aboBoNT-A.Study Supported by:Study supported by IpsenDisclosure: Dr. Rosales has received personal compensation for activities with Ipsen and Pfizer as a scientific advisory board member and consultant. Dr. Goh has received personal compensation for activities with Sanofi Genzyme as a moderator. Dr. Kumthorn...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Rosales, R., Goh, K. J., Kumthornthip, W., Mazlan, M., Latif, L. A., De Los Santos, M. M., Chotiyarnwong, C., Tanvijit, P., Balcaitiene, J., Maisonobe, P., Kong, K.-H. Tags: Neuro-rehabilitation: Motor Recovery and Spasticity Treatment Source Type: research
The Adult Spasticity International Registry (ASPIRE) Study: 1-Year Results (P4.034)
Conclusions:Findings demonstrate the real-world safety and effectiveness for onabotulinumtoxinA treatment in spasticity. Further analyses will explore clinical and burden outcomes and differences across etiology and presentation.Study Supported by: Allergan plcDisclosure: Dr. Francisco has received personal compensation for activities with Allergan, Ipsen, Mallinckrodt, and Merz. Dr. Francisco has received personal compensation in an editorial capacity for Journal of Rehabilitation Medicine. Dr. Francisco has received research support from Allergan, Ipsen, Mallinckrodt, Medtronic, Merz, Microtransponder, and Nexstim. Dr. B...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Francisco, G. E., Bandari, D. S., Bavikatte, G., Jost, W. H., Adams, A. M., Largent, J., Esquenazi, A. Tags: Neuro-rehabilitation: Motor Recovery and Spasticity Treatment Source Type: research
Duration of Treatment Effect of IncobotulinumtoxinA in Upper Limb Spasticity (P4.036)
Conclusions:These results demonstrate variability in the duration of treatment effect, which supports the use of flexible and individualized dosing intervals for the treatment of ULPSS. The duration of treatment effect was ≥14 weeks after most treatments; however, a considerable proportion of patients experienced effects lasting up to 20 weeks.Study Supported by: Merz Pharmacueticals GmbHDisclosure: Dr. Rubin has received personal compensation for activities with Allergan and Merz as a speaker and advisory board member. Dr. Kanovsky has received research support from Merz. Dr. Elovic has received personal compensation f...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Rubin, B., Kanovsky, P., Elovic, E., Munin, M., Althaus, M., Hanschmann, A., Pulte, I., Marciniak, C. Tags: Neuro-rehabilitation: Motor Recovery and Spasticity Treatment Source Type: research
Duration of effect of abobotulinumtoxina (dysport(r)) in adult patients with upper limb spasticity (uls) post-stroke or traumatic brain injury (p4.038)
Conclusions:These data show that 24% to 37% of subjects did not require re-injection before Week 16 across multiple cycles. This longer duration to re-treatment may reduce the burden associated with frequency of injections for patients and their caregivers/families. This also highlights the needs for a tailored approach in the treatment of patients with ULS.Study Supported by:Study supported by IpsenDisclosure: Dr. Gracies has received research support from Ipsen. Dr. Brashear has received personal compensation for activities with Ipsen, Worldmeds and Revance as a consultant. Dr. Marciniak has received personal compensatio...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Gracies, J.-M., Brashear, A., Marciniak, C., Jech, R., Banach, M., Marque, P., Grandoulier, A.-S., Vilain, C., Picaut, P. Tags: Neuro-rehabilitation: Motor Recovery and Spasticity Treatment Source Type: research
Effect of Rhythmic Auditory Stimulation On Gait In Patients With Stroke (P4.039)
Conclusions:Rhythmic auditory stimulation combined with treadmill training is effective in improving selected gait kinematics in stroke patients when added to the selected physical therapy program.Disclosure: Dr. Ibrahim has nothing to disclose. Dr. Mousa Ahmed has nothing to disclose. Dr. Mohamed Fahmy has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Ibrahim, M. A., Ahmed, G. M., Fahmy, E. M. Tags: Neuro-rehabilitation: Motor Recovery and Spasticity Treatment Source Type: research
The Effect of SSRIs in the Outcomes of ICARE Trial (P4.040)
Conclusions:Despite having similar baseline scores as non-SSRI users, SSRI users had 12-month PHQ-9 scores suggestive of mild depression while non-SSRI users did not. There was no imbalance in SSRI use for the 3 treatment arms, ruling out an effect on overall motor outcomes. SSRIs affected outcomes in the different trial arms in different ways which supports the hypothesis that medications can affect rehabilitation interventions.Study Supported by: National Institute of Neurological Disorders and Stroke, and the National Center for Medical Rehabilitation Research (U01 NS056256)Disclosure: Dr. Belagaje has nothing to disclo...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Belagaje, S., Blanton, S., Ding, L., Lane, C., Nelsen, M., Dromerick, A., Winstein, C., Wolf, S. Tags: Neuro-rehabilitation: Motor Recovery and Spasticity Treatment Source Type: research
Acute Ischemic Stroke as a Presenting Feature of Multiple Myeloma (P3.279)
Conclusions:Stroke is a leading and preventable cause of disability in the US adult population. The majority of strokes are due to atherosclerotic vascular or cardioembolic disease. Understanding the diagnostic work up of stroke and recognizing rare etiologies like MM is important for stroke prevention. This brings to light the importance of recognizing stroke as an initial presenting feature of multiple myeloma and of multiple myeloma as an important treatable etiology of stroke.Disclosure: Dr. Chung has nothing to disclose. Dr. Ramamoorthy has nothing to disclose. Dr. Kar has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Chung, S., Ramamoorthy, R., Kar, J. Tags: Cerebrovascular Disease Case Reports II Source Type: research
A case of drug-induced metabolic encephalopathy presenting to the stroke unit (P3.282)
Conclusions:This highly unusual case of acute drug-induced encephalopathy with profound thyrotoxicosis presents as a stroke-mimic. Cannabinoids are more typically associated with reversible cerebral vasoconstriction syndrome which was not present here illustrating an important point that there is much less certainty about the actual content of recreational drugs with the advent of ‘legal-highs’. We speculate as to whether his neurological presentation and thyrotoxicosis are related to his drug use or he has in fact two separate insults to his brain.Study Supported by: Not applicableDisclosure: Dr. Maduakor has ...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Maduakor, C., Vasan, S., Khan, U. Tags: Cerebrovascular Disease Case Reports II Source Type: research
Brain Embolism in the Moyamoya Syndrome (P3.290)
Conclusions:Hemodynamic compromise may not be the only cause of brain infarction in patients with moyamoya syndrome. Observations from these two patients provide both direct visualization and TCD evidence of embolization, suggesting an alternative, or additional, etiology for brain ischemia in these patients. Future investigations into the role of antithrombotic agents should be considered.Disclosure: Dr. Grimes has nothing to disclose. Dr. Snider has nothing to disclose. Dr. Vaitkevicius has received personal compensation for activities with Sage therapeutics as an employee. Dr. Babikian has received personal compensation...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Grimes, J., Snider, S., Vaitkevicius, H., Babikian, V., Patel, N. Tags: Cerebrovascular Disease Case Reports II Source Type: research
The Vertebral Body Infarct Sign: A Case of Thoracic Spinal Cord Ischemic Stroke (P3.292)
Conclusions:While the vertebral body infarct sign is often recognized by neuro-radiologists, it is still relatively unknown to practicing neurologists. Early recognition of spinal cord infarct allows for timely evaluation for precipitating factors and initiation of secondary preventative therapies to decrease risk of further vascular events.Disclosure: Dr. Chan has nothing to disclose. Dr. Chan has nothing to disclose. Dr. Farooque has nothing to disclose. Dr. Nowak has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Chan, D., Chan, A., Farooque, P., Nowak, R. Tags: Cerebrovascular Disease Case Reports II Source Type: research
Intrapartum thrombolysis in acute stroke patient (P3.295)
Conclusions:The AHA/ASA guidelines recommend alteplase for moderate to severe strokes in pregnancy provided the benefit justifies the potential risk to the fetus and mother. Although, we report successful administration of intravenous alteplase during active labor without any complication to mother and baby, more data is needed to confirm the efficacy and safety in this patient population. A retrospective cohort study of 15 cases of alteplase in pregnancy did not demonstrate any increase in adverse events when compared to the non-pregnant females but none of them were in labor.Disclosure: Dr. Kohli has nothing to disclose....
Source: Neurology - April 17, 2017 Category: Neurology Authors: Kohli, D., Shekhar, S., Sreenivasan, V., Sugg, R. Tags: Cerebrovascular Disease Case Reports II Source Type: research
Endovascular Therapy for Acute Ischemic Stroke with Distal Middle Cerebral Artery Occlusion; A Case Series (P3.300)
Conclusions:Our initial experience suggests that successful recanalization of M2 and M3 occlusion with EVT is feasible and safe. Larger studies would help identifying benefit of EVT in this subset of intracranial occlusions.Disclosure: Dr. Suriya has nothing to disclose. Dr. Quadri has nothing to disclose. Dr. Taqi has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Suriya, S., Quadri, S., Taqi, M. Tags: Cerebrovascular Disease Case Reports II Source Type: research
Post-Stroke Disability at a National Referral Hospital in Tanzania (P3.322)
Conclusions:In this low-resource setting, individuals with stroke face a severe burden of disability and high risk of mortality. The majority of participants experienced severe deficits following stroke, as assessed through NIHSS and mRS. While this study may be limited by referral bias, the high toll of disability among this population suggests that post-stroke disability places a significant burden on Tanzanian families and society.Study Supported by:This abstract was made possible with help from the Harvard University Center for AIDS Research (CFAR), an NIH funded program (P30 AI060354), subgrant to F. Mateen.Disclosure...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Wibecan, L., Mmbando, T., Grundy, S., Klein, J., Mateen, F., Okengo, K. Tags: Global Health Source Type: research
